An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer

Recruiting Observational Study
Hepatocellular Carcinoma (HCC) Liver Cancer, Adult Liver Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
80 (estimated)
Sponsor
University Hospital, Ghent · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Transarterial radioembolization (TARE) is a key treatment option for patients with unresectable hepatocellular carcinoma (HCC), a primary form of liver cancer. TARE is a minimally invasive therapy in which radioactive microspheres are delivered through a microcatheter near the tumour into the liver's blood vessels. Although TARE can significantly improve survival, treatment outcomes remain variabl…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Subjects radiologically diagnosed with HCC, eligible for or undergoing treatment. * Subjects who are treated (or will be treated) using TARE with radioactive microspheres. * Subjects for whom pre-treatment medical imaging of the hepatic arterial vasculature was performed for T…
Contacts

Elisabeth Dhondt, Dr.

+32 9 3326684

Elisabeth.dhondt@uzgent.be

CONTACT